A Phase 2 Study to Evaluate Safety and Efficacy of EB-001 Intramuscular (IM) Injections in Reducing Musculoskeletal Pain in Subjects Undergoing Elective Abdominoplasty Surgery
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2018
At a glance
- Drugs Botulinum toxin E (Primary)
- Indications Musculoskeletal pain
- Focus Registrational; Therapeutic Use
- Acronyms LANTERN-2
- Sponsors Bonti
- 17 Oct 2018 Status changed from recruiting to discontinued.
- 09 May 2018 According to a Bonti media release, first patient has been dosed, and topline results are expected in the fourth quarter of 2018.
- 09 May 2018 Status changed from not yet recruiting to recruiting, according to a Bonti media release.